A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection.

ABSTRACT:

Background

Epstein-Barr virus (EBV) is a significant global public health concern because of its association with various malignancies and autoimmune diseases. Over 90% of the global population is chronically infected with EBV, impacting numerous cancer-related cases annually. However, none of the effective prophylactic vaccines against EBV is approved at present.

Methods

In this study, we developed a novel vaccine candidate based on epitope peptides from the receptor-binding domain of EBV-encoded gp350 glycoprotein to prevent EBV infection. These epitope peptides detected a binding capability with host cells were then fused by flexibility linkers and expressed in Escherichia coli to reduce the unnecessary glycan modifications to simulate their free-glycan status. The

SUBMITTER: Li P 

PROVIDER: S-EPMC11739326 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature